Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers
|
On April 2, 2019, Nolan Sigal, M.D., Ph.D. was elected to the
Board of Directors (the Board) of Aileron Therapeutics, Inc. (the Company) as a Class II director with a term expiring at the 2019 annual meeting of stockholders, effective upon the closing of the Companys
previously announced private placement. The Board also appointed Dr. Sigal to serve on the Boards Compensation Committee and Nominating and Corporate Governance Committee.
Dr. Sigal currently serves as a partner at Satter Management Co., L.P., a private investment firm, a position he has held since January
2018. From March 2008 to December 2017, Dr. Sigal was the president and chief executive officer of Tunitas Therapeutics, Inc., a private biopharmaceutical company. Prior to 2008, Dr. Sigal held various leadership positions with several
public and private pharmaceutical and biotechnology companies, including several management positions at Merck & Company. Dr. Sigal received an A.B. from Princeton University and an M.D. and Ph.D. from the University of Pennsylvania
School of Medicine.
Dr. Sigal was appointed to the Board and each Board committee pursuant to the terms of the Securities Purchase
Agreement, dated as of March 28, 2019, between the Company and the Investors party hereto, relating to a previously announced private placement of securities. The Board also determined to nominate Dr. Sigal for election as a Class II
director at the 2019 annual meeting of stockholders and to recommend that the stockholders of the Company vote for his election as a Class II director at the 2019 annual meeting of stockholders.
Dr. Sigal has no family relationships with any director, executive officer or any person nominated or chosen by the Company to become a
director or executive officer.
In accordance with the Companys director compensation program, Dr. Sigal will receive an annual
cash fee of $35,000 for service on the Board and an additional cash fee of $10,000 and $7,500 for service on the Boards Compensation Committee and Nominating and Corporate Governance Committee, respectively, which fees are payable in arrears
in four quarterly installments on the last day of each calendar quarter. In addition, under the Companys director compensation program, upon his election as a director, Dr. Sigal was granted an option on April 2, 2018 to purchase
20,000 shares of the Companys common stock at an exercise price of $1.82. This option vests in three equal annual installments from his initial election and becomes exercisable in full upon the occurrence of a change of control of the Company.
In connection with his appointment to the Board, Dr. Sigal also entered into the Companys standard form of indemnification
agreement, a copy of which was filed as Exhibit 10.12 to Amendment No. 1 to the Companys Registration Statement on Form
S-1
(File
No. 333-218474)
filed
with the Securities and Exchange Commission on June 19, 2017. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Dr. Sigal for some expenses, including attorneys fees, judgments,
fines and settlement amounts incurred by him in any action or proceeding arising out of his service as a director of the Company.